Tags : Vertex

PharmaShots Weekly Snapshot (September 30–October 04, 2019)

1. Arbutus to Discontinue its P-Ia/Ib Clinical Study of AB-506 to Treat Patients with Chronic Hepatitis B Published: Oct 03, 2019 | Tags: Arbutus, Discontinue, P-Ia/Ib, Clinical Study, AB-506, Chronic Hepatitis B 2. Janssen’s Niraparib Receives the US FDA’s Breakthrough Therapy Designation for Metastatic Castration-Resistant Prostate Cancer Published: Oct 03, 2019 | Tags: Janssen, Niraparib, Receives, US, […]Read More

PharmaShots Weekly Snapshot (September 09 – 13, 2019)

1. Eisai And Biogen to Terminate Two P-III Clinical Studies of Elenbecestat (E2609) for Early Alzheimer’s Disease Published: Sept 13, 2019 | Tags: Eisai, Biogen, Terminate Two, P-III, Clinical Studies, Elenbecestat, E2609, Early Alzheimer’s Disease 2. GE Healthcare’s Critical Care Suite AI-Powered X-ray Device Receives FDA’s 510(k) Clearance to Identify Pneumothorax Published: Sept 12, 2019 | Tags: […]Read More

Vertex Signs an Access Agreement with Scottish Government for Orkambi

Shots: The access agreement allows patients with eligible cystic fibrosis to access Orkambi and Symkevi (tezacaftor/ivacaftor) in combination with ivacaftor in Scotland Vertex will collect real-world data on the combination therapies which will support future regulatory submission to the Scottish Medicines Consortium (SMC) following the 5yrs. access agreement Orkambi is a combination therapy used to […]Read More

PharmaShots Weekly Snapshot (September 02 – 06, 2019)

1.Roche’s Tecentriq + Chemotherapy Receives EC’s Approval as 1L Treatment for Extensive Stage Small Cell Lung Cancer Published: Sept 06, 2019 | Tags: Roche, Tecentriq, Chemotherapy, Receives, EC, Approval, Initial Treatment, Extensive Stage Small Cell Lung Cancer 2. OncoCyte to Acquire Razor Genomics for the Expansion of its Capabilities in Early-Stage Lung Cancer Published: Sept 05, 2019 […]Read More

Vertex to Expand its Collaboration with CRISPR Therapeutics to Develop

Shots: Vertex signs a licensing agreement with CRISPR to develop & discover gene editing therapies for DMD and DM1. CRISPR to get $1B, as total deal value including $175M upfront, milestones and royalties on sales. Vertex to get exclusive WW rights for IPR of gene editing therapies including foundational CRISPR/Cas9 technology, novel endonucleases, single and […]Read More

Vertex Signs a 4 Years Agreement with Kymera to Discover

Shots: Kymera to receive $70M upfront including equity investment, >$1B as development, regulatory & commercial milestones for up to 6 therapies opted by Vertex, royalties on sales of products and is responsible for clinical research activities. Vertex to get an option to license the developed molecules against designated targets The focus of the collaboration is […]Read More